A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

Plain Language SummaryWhat is this summary about? In the SAVANNAH study, patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC), which had grown or spread (known as ‘progressed’) on previous osimertinib treatment, were treated with savolitinib plus osimertinib.Patients had NSCLC tumors with: An epidermal growth factor receptor (EGFR) mutation.Increased levels of the MET protein (overexpression) or extra copies of the MET gene (amplification).What are the key takeaways? Of the 80 patients in the group of patients in which treatment effectiveness was assessed (known as the ‘primary efficacy population’), just over half (56%) had tumors that shrunk (known as a ‘tumor response’).In half of all patients who had a tumor response, the response continued for 7.1 months after the response started (known as ‘median duration of response’).The time at which half of the patients were alive, without their cancer having grown or spread (known as ‘median progression‐free survival’) was 7.4 months.What were the main conclusions reported by the researchers? Treatment with savolitinib plus osimertinib was associated with a high likelihood of tumor response in patients with EGFR-mutated advanced NSCLC and high levels of MET overexpression and/or amplification after previous osimertinib treatment.Side effects were considered tolerable and similar to those seen in other studies of savolitinib or osimertinib.Savolitinib plus osimertinib may provide a new targeted treatment option for these patients.Clinical trial number: NCT03778229

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-07-16
DOI
https://doi.org/10.1080/14796694.2026.2692029
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

Yasuto Yoneshima, Jong Seok Lee, Desirée Hao, Yung‐Hung Luo et al.
Future Oncology
Lung Cancer Treatments and Mutations
article

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

Yasuto Yoneshima, Jong Seok Lee, Desirée Hao, Yung‐Hung Luo, Claudia Proto, Giulio Metro, J Cadranel, Susanna Cheng, Byoung Chul Cho, S Kim, Wanning Xu, Tuan Bao Diep, Tae Min Kim, Prasad Narayanan, Lynne Poole, Ike Igwegbe, Laura Bonanno, L Sequist, Quincy Chu, Clarissa Baldotto, Javier de Castro Carpeño, Ryan Hartmaier, Christina Baik, Myung-Ju Ahn, Silvia Novello, James Chih-Hsin Yang, Filippo de Marinis, Lyudmila Bazhenova, Adrian Sacher, Benjamin Levy, Marcello Tiseo
article en

Abstract

Plain Language SummaryWhat is this summary about? In the SAVANNAH study, patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC), which had grown or spread (known as ‘progressed’) on previous osimertinib treatment, were treated with savolitinib plus osimertinib.Patients had NSCLC tumors with: An epidermal growth factor receptor (EGFR) mutation.Increased levels of the MET protein (overexpression) or extra copies of the MET gene (amplification).What are the key takeaways? Of the 80 patients in the group of patients in which treatment effectiveness was assessed (known as the ‘primary efficacy population’), just over half (56%) had tumors that shrunk (known as a ‘tumor response’).In half of all patients who had a tumor response, the response continued for 7.1 months after the response started (known as ‘median duration of response’).The time at which half of the patients were alive, without their cancer having grown or spread (known as ‘median progression‐free survival’) was 7.4 months.What were the main conclusions reported by the researchers? Treatment with savolitinib plus osimertinib was associated with a high likelihood of tumor response in patients with EGFR-mutated advanced NSCLC and high levels of MET overexpression and/or amplification after previous osimertinib treatment.Side effects were considered tolerable and similar to those seen in other studies of savolitinib or osimertinib.Savolitinib plus osimertinib may provide a new targeted treatment option for these patients.Clinical trial number: NCT03778229

Future Oncology
Ontario Institute for Cancer Research (CA), University of Parma (IT), Sunnybrook Health Science Centre (CA), Kyushu University (JP), University of Padua (IT), Johns Hopkins University (US), National Yang Ming Chiao Tung University (TW), University of Calgary (CA), University of Toronto (CA), Yonsei University (KR), University of Perugia (IT), Hospital Universitario La Paz (ES), Samsung Medical Center (KR), Princess Margaret Cancer Centre (CA), Seoul National University Hospital (KR), Taipei Veterans General Hospital (TW), Seoul National University Bundang Hospital (KR), University of California San Diego (US), Sorbonne Université (FR), University of Ulsan (KR), London Rebuilding Society (GB), Massachusetts General Hospital (US), Azienda Ospedaliera di Perugia (IT), Fred Hutch Cancer Center (US), Comprehensive Cancer Center Vienna (AT), Assistance Publique – Hôpitaux de Paris (FR), D’Or Institute for Research and Education (BR), Hospital La Paz Institute for Health Research (ES), Istituto Oncologico Veneto (IT), AstraZeneca (Netherlands) (NL), HCG Cancer Hospital (IN), AstraZeneca (Singapore) (SG), HCMC Hospital of Dermato Venereology (VN), Ospedale Santa Maria (IT), AstraZeneca (Japan) (JP), National Taiwan University Hospital (TW), AstraZeneca (Poland) (PL), Center for Cancer Research (US), AstraZeneca (United States) (US), Ospedale San Luigi Gonzaga (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Sidney Kimmel Comprehensive Cancer Center (US), Hôpital Tenon (FR), THERANOSCAN : Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules, University of Turin (IT), European Institute of Oncology (IT)
Quality Education
Openalex Percentile: Top 9%
Lung Cancer Treatments and Mutations
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.